Cataract
Conditions
Brief summary
This clinical study is a randomized, controlled, open, prospective, multi-centre, multi-surgeon post-market-clinical-follow-up study to investigate the impact of cataract grade on the efficacy and safety of femtosecond laser assisted lens fragmentation to support phacoemulsification of the cataractous lens prior to intraocular lens (IOL) implantation.
Detailed description
The purpose of the multi-centre, multi-surgeon, randomized, controlled, prospective, post-market-clinical-follow-up study clinical study is to investigate the impact of cataract grade on the safety and efficacy of femtosecond laser assisted lens fragmentation for cataract surgery by using VICTUS femtosecond laser platform. In this study patients with different cataract grades \[judged by lens opacity classification system (LOCS) III on nuclear opalescence) will be randomly assigned to either a manual group or a laser group, and aspects on efficacy and safety will be investigated. * The sponsor and the investigators ensure, that all relevant documents are approved by their institutional review board / institutional ethics committee (IRB/IEC), or if not using their institution's IRB/IEC, approved by the reviewing central IRB/IEC prior to entering any subjects in the study. * To avoid any potential bias during the process of patient assignment and in order to observe fair and true clinical significance a block randomization method will be employed and applied during the study. * Subjects are regarded as enrolled to the clinical trial population as soon as they have signed and received the patient informed consent form (ICF) and underwent preoperative examinations. * The sponsor's clinical group will accompany and monitor this study in respect to patient enrolment, eligibility control, randomization process, postoperative monitoring and data collection in accordance with the applicable regulations and the specifications required by the sponsor. * All medical information obtained at each study visit will be recorded in the subject's record (source documentation) in real time as it is collected and then transcribed onto the case report form (CRF) by site personnel.
Interventions
The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens. The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process. Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status. All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.
PROCEDUREManual cataract surgery
Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Sponsors
Technolas Perfect Vision GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have read, understood and signed the Patient Information * Patients are willing and able to return for follow-up examinations * Clear corneal media * Cataract grade (nuclear) from I to V according to LOCS III * Patients must be at least 40 years of age
Exclusion criteria
* Patients presenting a clear lens (clear lens exchange) * Glaucoma and suspected glaucoma * Patients with pre-existing proliferative diabetic retinopathy (mild and tight controlled diabetes symptoms, without retinopathy and non-proliferative diabetic retinopathy, can be included.) * Retinal disorders * Rheumatic diseases * Occlusion of retinal vessels * Pellucid marginal degeneration * Herpes zoster or herpes simplex keratitis * Heavy vascularization of the ocular tissue * Epilepsy * Recurrent corneal erosion * Severe basement membrane disease * Patients who suffer from severe wound-healing disorders such as connective tissue disease, autoimmune illnesses, immunodeficiency illnesses,endocrine diseases, lupus, rheumatoid arthritis, collagenosis, or clinically significant atopy * Patients suffering from AIDS or HIV. * Chemosis * Significant loss of stability of the conjunctiva * Nystagmus * On a keratometric map of the cornea, the minimum and maximum K-values of the central 3 mm zone must not differ by more than 5 D. * The maximum K-values must not exceed 60 D. The minimum value must not be smaller than 37 D. * Patients who are pregnant or nursing. * Patients who are blind in the fellow eye. * Known sensitivity to planned concomitant medications. * Patients with a recurrent or active ocular or uncontrolled eyelid disease. * Subjects with a poorly dilating pupil. * Patients with an anterior chamber depth (ACD) \< 1.5 mm or ACD \> 4.8 mm * Presence of blood or other material in the anterior chamber. * A history of lens instability (eg. posterior polar cataract, traumatic cataract) or zonular instability
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effective Phacoemulsification Time | This criterion should be achieved at the day of treatment. | The effective phacoemulsification time (EPT) used the Laser group (pooled from all grades) during phacoemulsification is lower than or equal to that in the Manual group (pooled from all grades); p\<0.05 will be considered statistically significant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | This purpose criterion should be achieved intraoperative, at 1 day, 1 week and 1 month. | Less or equal adverse events (e.g. retinal detachment, IOL malposition, etc.) in Laser group (pooled from all cataract grades) compared with Manual group (pooled from all cataract grades); p\<0.05 will be considered statistically significant. The secondary study end point is only based on adverse events and severe adverse events which are related to the treatment procedures. |
Countries
Czechia, India
Outcome results
None listed